Researchers at the University of Southern California (USC) have announced a significant advancement in the field of cancer immunotherapy, developing a method to generate an effectively endless supply of cancer-fighting T cells. This breakthrough addresses a critical limitation in current cell-based cancer treatments, which often struggle with the scalability and consistency of immune cell production. The USC team has engineered a 'master cell bank' of T cells that can be continuously replenished. This approach is akin to stem cell technology, allowing for the generation of therapeutic T cells on demand. This innovation is expected to overcome the challenges associated with the slow and often insufficient expansion of T cells required for treatments such as CAR-T therapy. According to ScienceAlert, the ability to produce a virtually unlimited quantity of these immune cells could dramatically accelerate treatment timelines for patients and potentially reduce the overall cost of these advanced therapies. The researchers' work, detailed in ScienceDaily, marks a pivotal step toward making potent immunotherapies more accessible and effective in the fight against various cancers.